This page lists the gynaecology hospitals in our directory offering Colposcopy in Dubai, UAE, including Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai. Each listing links through to the hospital's full profile page.
Ask us about colposcopy in Dubai, UAE
Share a few details and our care coordination team will get back to you with next steps.
Compare 3 accredited hospitals for Gynaecology in Dubai, UAE
Featured🇦🇪 Burjeel Hospital for Advanced Surgery Dubai
Ranks #1 in this list by listed rating (4.5/5 from 1 reviews).
🇦🇪 Kings College Hospital Dubai
Ranks #2 in this list by listed rating (4.5/5 from 1 reviews).
🇦🇪 Aster Hospital Dubai
Ranks #3 in this list by listed rating (4.5/5 from 1 reviews).
How we selected these hospitals
A hospital appears on this page when Gynaecology is among its listed specialties and it is located in Dubai, UAE. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Colposcopy in Dubai, UAE?
Choosing the right hospital for colposcopy is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include gynaecology rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Colposcopy
Colposcopy is a minimally invasive diagnostic procedure used to closely examine the cervix, vagina, and vulva for signs of disease, particularly precancerous lesions and abnormal cell changes detected on Pap smear or HPV testing. The procedure carries a near-100% diagnostic accuracy rate when performed by experienced colposcopists, and directed biopsy adds tissue-level confirmation to guide treatment decisions. GAF Healthcare connects international patients with JCI- and NABH-accredited hospitals in India and JCI- and DHA-accredited facilities in Dubai and Abu Dhabi, offering expert gynaecological oncology care at a fraction of Western costs with full end-to-end travel support. Hospital Stay: 0–1 days (day procedure; overnight admission rare) • Total Stay in Country (Fit-to-Fly): 3–7 days (short-haul); 5–10 days (long-haul international flight) • Success Rate: 95–98% diagnostic accuracy; 90–95% clearance of CIN lesions with directed treatment
Clinical Overview
Colposcopy is a secondary-level gynaecological investigation performed when a primary cervical screening test — such as a liquid-based cytology (LBC) Pap smear or high-risk HPV (hrHPV) co-test — returns an abnormal or unsatisfactory result. Using a colposcope, a binocular magnifying instrument with co-axial illumination (typically 6× to 40× magnification), the clinician applies dilute acetic acid (3–5%) and Lugol's iodine (Schiller's test) to the transformation zone of the cervix to identify acetowhite epithelium, punctation, mosaicism, and atypical vessels — the hallmark colposcopic patterns of cervical intraepithelial neoplasia (CIN). The grading of colposcopic impression follows the International Federation for Cervical Pathology and Colposcopy (IFCPC) 2011 Nomenclature, stratifying findings into normal, minor-change (Grade 1), major-change (Grade 2), and suspicious-for-invasion categories. Physiologically, the cervical transformation zone (TZ) — particularly the squamocolumnar junction (SCJ) — is the site of highest oncogenic risk because metaplastic squamous cells replacing columnar epithelium are susceptible to persistent hrHPV (genotypes 16, 18, 31, 33, 45) integration and subsequent p53/Rb pathway disruption. Left undetected and untreated, high-grade CIN 2–3 carries a 30–50% lifetime risk of progression to invasive squamous cell carcinoma or adenocarcinoma of the cervix over 10–20 years. Colposcopy interrupts this continuum by enabling targeted colposcopically directed punch biopsy (1–3 samples, 3 mm Kevorkian or Eppendorfer forceps) and, when indicated, endocervical curettage (ECC) to histologically confirm the diagnosis before any ablative or excisional treatment is undertaken. The contemporary standard of care in high-volume gynaecological oncology centres — as practised across India and the UAE — integrates digital video colposcopy with high-definition imaging, real-time documentation for multidisciplinary team review, and HPV genotyping to risk-stratify management. Patients with confirmed CIN 1 may be managed conservatively with active surveillance at 12-month intervals, while CIN 2–3 or adenocarcinoma in situ (AIS) is treated definitively by excisional procedures such as Large Loop Excision of the Transformation Zone (LLETZ/LEEP) or cold-knife conisation (CKC), often performed during the same colposcopy visit (see-and-treat protocol) in high-risk scenarios.
Who is a Candidate?
• Women with an abnormal Pap smear result: atypical squamous cells of undetermined significance (ASC-US), atypical squamous cells — cannot exclude HSIL (ASC-H), low-grade squamous intraepithelial lesion (LSIL), or high-grade squamous intraepithelial lesion (HSIL) • Women with a positive hrHPV test (especially HPV 16 or 18) regardless of cytology result, as per risk-based management guidelines (ASCCP 2019) • Women with unexplained post-coital bleeding, intermenstrual bleeding, or persistent vaginal discharge not explained by infection • Women with a clinically suspicious-looking cervix on speculum examination (irregular surface, friable tissue, contact bleeding) • Follow-up surveillance after prior treatment for CIN, VAIN, or cervical cancer • Women with a history of DES (diethylstilbestrol) in utero exposure • Evaluation of VIN (vulvar intraepithelial neoplasia) or VAIN (vaginal intraepithelial neoplasia) in conjunction with extended colposcopy Required Pre-Procedure Diagnostics: • Recent Pap smear / LBC cytology report and HPV genotyping result (within 12 months) • Transvaginal ultrasound (TVS) if uterine or adnexal pathology is suspected • STI screen (Chlamydia, Gonorrhoea, Trichomonas) — active pelvic infection is a relative contraindication • Beta-hCG (urine or serum pregnancy test) — colposcopy can be performed in pregnancy, but ECC is contraindicated • Complete blood count (CBC) and coagulation profile (PT/INR, aPTT) if biopsy or excision is anticipated • Renal and liver function tests if patient is on anticoagulant therapy Contraindications: • Active, uncontrolled pelvic inflammatory disease (PID) — defer until treated • Endocervical curettage (ECC): absolutely contraindicated in pregnancy • Anticoagulation therapy (relative): requires bridging plan in coordination with haematology • Severe vaginal atrophy making speculum insertion traumatic — pre-treat with topical oestrogen for 4–6 weeks
Treatment Options & Approaches
Colposcopy encompasses both a diagnostic procedure and, where clinically indicated, same-session therapeutic intervention. The following techniques represent the current spectrum of colposcopic practice at advanced gynaecological centres: 1. STANDARD DIAGNOSTIC COLPOSCOPY Performed under direct colposcopic visualisation using a Leisegang, Zeiss, or equivalent binocular colposcope. Sequential application of 3–5% acetic acid followed by Lugol's iodine allows grading of the transformation zone type (TZ1: fully ectocervical and visible; TZ2: partially endocervical; TZ3: fully endocervical) per IFCFC 2011 criteria. Colposcopically directed punch biopsies (1–4 samples) are taken from the highest-grade areas. ECC is added when TZ3 is present or when cytology-colposcopy discordance exists (cytology HSIL but colposcopy low-grade). 2. DIGITAL VIDEO COLPOSCOPY WITH AI-ASSISTED IMAGE ANALYSIS High-definition (HD) digital colposcopes (e.g., Lutech, Olympus OCS-500) capture real-time video and still images for archiving, second-opinion review, and AI-assisted acetowhite lesion detection. Several JCI-accredited centres in India and the UAE now use machine-learning algorithms (e.g., CAIIBM, EVA colposcopy software) trained on thousands of colposcopic images to flag Grade 2 lesions with sensitivity comparable to expert colposcopists, reducing inter-observer variability. 3. NARROW BAND IMAGING (NBI) COLPOSCOPY NBI uses filtered light (415 nm blue, 540 nm green) to enhance visualisation of superficial capillary architecture — punctation, mosaicism, and atypical vessels — without acetic acid application. This technique is particularly valuable in postmenopausal or immunocompromised patients where acetowhitening is less pronounced and in identifying the neovascular patterns of early invasive disease (IFCPC 2011: irregular vessels, necrosis, wide intercapillary distance). 4. LARGE LOOP EXCISION OF THE TRANSFORMATION ZONE (LLETZ / LEEP) The most commonly performed excisional treatment for CIN 2–3. A thin wire loop electrode (15–25 mm width, 8–12 mm depth) energised at 30–50 W blend current (electrosurgical unit: Valleylab FT10, ERBE VIO) excises the entire transformation zone en bloc under local anaesthetic (cervical block: 2–4 mL 1% lignocaine with 1:100,000 adrenaline at 3, 5, 7, and 9 o'clock). The LLETZ specimen provides a histological margin assessment — endocervical and ectocervical margins — guiding the adequacy of excision. Same-session see-and-treat LLETZ (colposcopy + LLETZ in one visit) is offered to patients with high clinical probability of CIN 2–3 (HSIL cytology + Grade 2 colposcopy). 5. COLD-KNIFE CONISATION (CKC) Reserved for adenocarcinoma in situ (AIS), recurrent CIN after LLETZ, or a TZ3 that is inadequately accessible to loop excision. A scalpel cone is taken under general or spinal anaesthesia, providing a larger specimen with thermal-artefact-free margins — critical for precise histological interpretation of glandular lesions. 6. ABLATIVE THERAPIES (selected cases of CIN 1–2 with fully visible TZ1–2) • Cryotherapy: Nitrous oxide or CO₂ at −89°C applied in a 3-minute freeze / 5-minute thaw / 3-minute freeze protocol. Suitable for CIN 1 in resource-limited or screen-and-treat settings (WHO guidelines). • Laser Ablation (CO₂ laser, 10,600 nm): Precise depth control (5–7 mm) under colposcopic guidance; preferred for multifocal or large-area CIN in well-equipped centres in India and UAE. • Thermal Ablation / Thermocoagulation: Contact thermocoagulation at 100–120°C; increasingly used in low-resource WHO screen-and-treat programmes. 7. HPV VACCINATION AS ADJUNCT (post-treatment) For patients under 45 years with no prior vaccination, quadrivalent (Gardasil-4) or nonavalent (Gardasil-9) HPV vaccination is recommended post-LLETZ to reduce the risk of recurrent CIN from residual or re-acquired HPV infection, supported by randomised controlled evidence (Joura et al., NEJM 2012).
Recovery
PRE-PROCEDURE (Days –7 to –1): • GAF Healthcare patient coordinator reviews all prior cytology, HPV test results, and imaging reports and shares them with the assigned colposcopist for pre-procedure planning. • Pelvic infection screen and pregnancy test are completed within 7 days of procedure. • Patient is advised to schedule the procedure for mid-cycle (days 10–20) to avoid menstrual blood obscuring visualisation — though colposcopy can be performed at any time. • Avoid intercourse, vaginal douching, and intravaginal medications for 24 hours prior. • If anticoagulants (warfarin, DOACs) are in use, haematology consultation is arranged 5–7 days in advance for bridging protocol. • No fasting required (procedure is outpatient under local anaesthetic or without anaesthesia). DAY OF PROCEDURE: • Patient arrives at the colposcopy clinic or outpatient gynaecology unit 30–60 minutes before the appointment. • Consent is obtained covering the procedure, biopsy, possible LLETZ, and risks (bleeding, infection, mild cramping). • Patient is placed in dorsal lithotomy position; a bivalve speculum is inserted. • Cervix is cleaned with normal saline; acetic acid 3–5% is applied — patients may feel mild stinging. • Colposcopic examination takes 10–20 minutes for diagnostic colposcopy alone. • Directed biopsies are taken (1–4 samples) using Kevorkian or Eppendorfer forceps — patient experiences a brief, sharp pinch with each biopsy. • ECC, if indicated, takes 1–2 additional minutes; produces uterine cramping similar to dysmenorrhoea. • If same-session LLETZ is performed, a cervical block is administered (onset 2–3 minutes), loop excision takes 2–5 minutes, and haemostasis is achieved with ball-electrode coagulation or Monsel's ferric subsulfate solution. • Total procedure time: 20–45 minutes. • Patient rests in recovery for 30–60 minutes, then is discharged home. IMMEDIATE POST-PROCEDURE (Hours 1–24): • Mild pelvic cramping for 2–6 hours — managed with ibuprofen 400 mg or paracetamol 1 g orally. • Light vaginal spotting or dark brown discharge (from Monsel's solution) is expected and normal for 1–3 days after biopsy; up to 2–3 weeks after LLETZ. • Patient is advised to avoid sexual intercourse, tampons, and swimming for 4 weeks post-LLETZ (2 weeks post-biopsy only). • Avoid strenuous exercise for 1 week post-biopsy; 2–3 weeks post-LLETZ. SHORT-TERM RECOVERY (Days 2–14): • Histopathology results are typically available within 5–10 business days (expedited 3–5 days at premium centres). • GAF Healthcare coordinates secure digital transfer of histology reports to the patient's home-country gynaecologist. • Warning signs requiring immediate medical attention: heavy bleeding (soaking more than one pad per hour), fever >38°C, foul-smelling discharge, or severe abdominal pain — patients are provided 24/7 GAF Healthcare emergency contact. FIT-TO-FLY MILESTONES: • Diagnostic colposcopy with biopsy only: fit to fly within 3–5 days if no significant bleeding and histology can be transferred digitally. • Colposcopy + LLETZ/LEEP: fit for short-haul flight (under 4 hours) in 5–7 days; long-haul international flight in 7–10 days, once bleeding has settled, infection risk window has passed, and histology is available. • Patient is provided a fit-to-fly letter by the treating gynaecologist. LONG-TERM FOLLOW-UP (Months 1–24): • Post-biopsy (CIN 1): surveillance HPV/cytology co-test at 12 months, then 24 months. • Post-LLETZ (CIN 2–3): test of cure HPV test at 6 months; if hrHPV negative and cytology normal, return to routine 3-year screening. • Post-LLETZ (AIS): annual surveillance for 5 years given higher recurrence risk. • All follow-up is coordinated with the patient's local gynaecologist via GAF Healthcare's international care continuity programme.
Risks to be aware of
Colposcopy is among the safest procedures in gynaecology, but patients must be counselled on the following specific risks: Diagnostic Colposcopy with Biopsy: • Bleeding: Minor spotting is expected in virtually all patients. Clinically significant bleeding requiring Monsel's application or silver nitrate cautery occurs in approximately 1–2% of biopsied patients. Rarely (<0.1%), active bleeding requiring a suture or re-attendance is required. • Infection/Pelvic Inflammatory Disease: Estimated at <1%; risk is mitigated by pre-procedure STI screening and post-procedure hygiene advice. Prophylactic antibiotics are not routinely given. • Discomfort/Vasovagal Response: Approximately 3–5% of patients experience a vasovagal episode (pre-syncope) during biopsy or ECC, particularly nulliparous women — managed with Trendelenburg positioning and reassurance. • Sampling Error (False Negative): Even expert colposcopy with directed biopsy has a miss rate for CIN 2+ of approximately 5–15%, which is why cytology-colposcopy-histology correlation is mandatory and follow-up is non-negotiable. LLETZ/LEEP-Specific Risks: • Immediate haemorrhage: 1–2%; may require haemostatic suture under local anaesthetic. • Delayed secondary haemorrhage (7–14 days post-procedure): 1–3%; associated with sloughing of the eschar. Requires emergency gynaecological review. • Cervical stenosis: 1–2%, more common in postmenopausal women; can complicate future endometrial sampling. • Cervical incompetence and preterm birth risk: Meta-analyses (Arbyn et al., BMJ 2017) demonstrate a relative risk of ~1.87 for preterm delivery (<37 weeks) after LLETZ; the absolute risk increase is small but must be disclosed to women of reproductive age. Risk is proportional to cone depth — deeper excisions (>10 mm) carry higher risk. • Incomplete excision: Positive margins at endocervical or ectocervical margin in approximately 15–25% of LLETZ specimens; associated with higher CIN recurrence rate, necessitating closer surveillance or re-excision. • Thermal artefact: High-frequency electrosurgery produces a thermal lateral damage zone of 0.5–1.5 mm, which can occasionally compromise histological margin interpretation — relevant when AIS is suspected (argument for CKC in such cases). Pregnancy-Specific Considerations: • Colposcopy in pregnancy is safe and recommended when indicated. ECC is absolutely contraindicated. Biopsies should be limited to areas strongly suspicious for invasion, as bleeding risk is higher due to increased vascularity. Management of CIN in pregnancy is predominantly conservative with re-evaluation 8–12 weeks postpartum.
Why GAF Healthcare
GAF Healthcare provides a fully integrated, end-to-end non-medical support infrastructure for international patients travelling for colposcopy and gynaecological care: VISA ASSISTANCE: • India: GAF Healthcare's dedicated visa support team assists patients in applying for the Indian e-Medical Visa (e-MV), which is available to nationals of over 150 countries, grants a triple-entry 60-day stay, and is processed online within 3–5 business days. A hospital invitation letter, passport-size photographs, and proof of sufficient funds are required — our coordinators prepare and submit the complete documentation package on the patient's behalf. • UAE (Dubai / Abu Dhabi): Citizens of over 120 countries receive visa-on-arrival or are visa-exempt for the UAE (GCC, EU, US, UK, Australia, etc.). For patients requiring a prior visa, GAF Healthcare facilitates a medical treatment visa in coordination with the hospital's international patient services office. Dubai's medical tourism visa is issued for up to 90 days. AIRPORT TRANSFERS AND GROUND LOGISTICS: • Private, air-conditioned vehicle transfers are arranged for all airport-to-hotel and hotel-to-hospital legs. • Female patient escort options are available for patients travelling alone, in line with cultural preferences. ACCOMMODATION: • GAF Healthcare maintains partnerships with partner hotels at 1–3 km proximity to all affiliated hospitals in Mumbai, Delhi, Chennai, Hyderabad, Dubai, and Abu Dhabi, with negotiated medical tourism rates. • Rooms with in-room meal service, accessible bathrooms, and 24-hour concierge are standard for post-procedure recovery stays. • Attendant accommodation (single room for one accompanying family member) is included in all standard GAF Healthcare packages. LANGUAGE AND CULTURAL SUPPORT: • Dedicated patient coordinators fluent in Arabic, Russian, French, Swahili, Bangla, Uzbek, and other common patient-origin languages are assigned from the first inquiry. • Medical interpreters are available for consultation, consent, and discharge briefings at no additional charge. • Culturally sensitive care provisions — including female-only colposcopy suites, female gynaecologists upon request, and halal meal options — are arranged in advance. CLINICAL CONTINUITY: • Histopathology reports, operative notes, and follow-up plans are securely transferred to the patient's home-country gynaecologist via GAF Healthcare's encrypted health record portal. • A 24/7 post-procedure helpline staffed by clinical coordinators is available for the first 14 days after the procedure. • All partner hospitals in India are NABH- and/or JCI-accredited; UAE partners hold JCI accreditation and are licensed by DHA (Dubai) or DoH (Abu Dhabi), ensuring internationally benchmarked quality standards across both destinations.
Common questions about Colposcopy
What is the cost of colposcopy in India compared to the UAE?
How long do I need to stay in the country before I am fit to fly home after colposcopy?
What is the success rate of colposcopy, and how effective is treatment for abnormal cervical findings?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Colposcopy in Dubai, UAE
Discover the Top Hospitals for Colposcopy in Dubai, UAE
This page lists 3 accredited gynaecology hospitals in Dubai, UAE, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about colposcopy in Dubai, UAE
How many gynaecology hospitals are listed in Dubai, UAE?
How do you choose which hospitals to list?
How much does treatment cost in UAE?
Are there gynaecology hospitals for this in other UAE cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for colposcopy in Dubai, UAE.
Contact us to report an inaccuracy on this page.